Kornimate/medical-research-clean huggingface dataset:
genetic profile on predicting sensibility of preoperative chemoradiotherapy on locally advanced rectal carcinoma

Conditions: Rectal Neoplasms

Summary: the aim of this study is to find some genetic factors in predicting the sensibility of preoperative chemoradiotherapy for locally advanced rectal carcinoma.

for locally advanced rectal carcinoma,preoperative chemoradiotherapy(crt) achieved similar overall survival and better local control compared with postoperative therapy,so it was considered to be one of the standard therapy of these patients.but,not every one will be cured,the possible reason is the difference gene expression and mutation status among patients.so,we performed this trial to study the relationship between genetic factors and response of preoperative crt for locally advanced rectal cancer.

Eligibility criteria:
inclusion criteria: * pathologically confirmed rectal adenocarcinoma, preoperative stage ii / iii (t3-4n0 or t1-4n + m0). * distance from the lower bound of tumor to the anal verge is less than 12 cm. * kps score not less than 70 * can be tolerated chemotherapy and radiotherapy. * no history of radiation therapy to the pelvis. * non-allergic history of fluorouracil or platinum-based chemotherapy drugs. * full understanding of the study, the ability to complete all of the treatment plan, follow up the conditions and sign the informed consent. - exclusion criteria: * other malignancy (past or at the same time), does not include curable non-melanoma skin cancer and cervical carcinoma in situ; does not include resectable primary colon cancer (synchronous or metachronous). * pregnant or lactating patients. * fertility but did not use contraceptive measures. * existing active infection. * merge serious complications, can not tolerate the treatment, such as 6 months of myocardial infarction, mental illness, uncontrollable diabetes or uncontrollable hypertension or hypotension. * concurrent treatment with other anticancer drugs. * can not complete treatment or follow-up

Keywords: rectal carcinoma preoperative concurrent chemoradiotherapy
targeted pet/ct and pet/mri imaging of vascular inflammation

Conditions: Aortic Aneurysm, Abdominal; Carotid Atherosclerosis

Summary: stroke and abdominal aortic aneurysms (aaas) are common and highly lethal vascular diseases. angiogenesis and infiltration of inflammatory cells such as macrophages may cause stroke and aaas. the purpose of this study is to test pet/ct and pet/mri imaging to specifically detect those diseases using a new developed agent (18f-fpprgd2) that can target angiogenesis and macrophages.

20 subjects with either carotid bifurcation stenosis of \>50% by ultrasound on at least one side (10 patients) or advanced aaas (10 patients) and surgical intervention planned will be identified from physicians from the division of vascular surgery at stanford. either a pet/ct or a pet/mri will be performed for each subject: * pet/ct scans will be performed in 3d mode using ge discovery 600 or ge discovery 690 scanners (ge healthcare). * pet/mri scans will be performed using the novel pet/mri system at stanford, including a sensitive pet time-of-flight (tof) scanner with an advanced 3t mri scanner. the study patients will receive an intravenous administration of 10mci of the prescribed radiotracer (18f-fpprgd2). pet/ct or pet/mri images will be obtained starting 45-60 minutes after radiotracer administration. for pet/ct, each image acquisition will begin with a non-contrast ct scan obtained from the vertex through the mid-thighs of the subjects. for pet/mri, non-contrast images of the carotid or aorta will be performed. pet imaging will follow. patient's vital signs will be monitored during the procedure and a physician will be available if there is need for immediate medical attention. the pet images will be reconstructed with a standard iterative algorithm using ge software release 5.0. after the planned surgery, we will also assess the histopathological correlation between the disease lesions and pet/ct or pet/mri imaging characteristics.

Eligibility criteria:
inclusion criteria: * greater than 18 year-old at the time of radiotracer administration * provides written informed consent * patients diagnosed with either carotid artery stenosis or abdominal aortic aneurysms (aaas) as identified in vascular surgery, in whom a surgical procedure is scheduled * able to remain still for duration of an imaging procedure (about one hour). exclusion criteria: * less than 18 year-old at the time of radiotracer administration * unable to provide written informed consent * pregnant women * prior carotid or abdominal surgery * history of radiation therapy to the neck and abdomen * mri contraindications (including ferromagnetic objects or devices).

Keywords: aortic aneurysm, abdominal carotid stenosis atherosclerosis angiogenesis inflammation macrophages positron-emission tomography computerized tomography magnetic resonance imaging (18f)fpp(rgd)2
randomised study of mucositis prevention after radiochemotherapy treatment for head and neck cancer

Conditions: Severe Acute Mucositis; Head and Neck Cancer

Summary: this randomised, double-blind study will compare an oral immunomodulatory solution to a placebo for the prevention of acute severe mucositis in head and neck cancer patients treated surgically and concomitantly with radiochemotherapy. the investigators expect a decrease of 25% of severe acute mucositis in experimental arm.


Eligibility criteria:
inclusion criteria: * epidermal carcinoma proven histologically of the sphere orl (all locations except nasopharynx). * patients with tumours of the oral cavity, the oropharynx, the hypopharynx and the larynx treated initially by surgery and eligible for post-operative radio- chemotherapy concomitantly. nb. the patients with tumours of the larynx or hypopharynx are eligible if the radiotherapy to the oropharyngeal mucosa will be at least 54 gy and the mucositis can be visualised without the use of instruments. * radio-chemotherapy to be given postoperatively. * maximum delay of 8 weeks between the operative date and the planned starting date of radio-chemotherapy. * performance status (grade oms): 0, 1, 2 * nutritional risk index ≥ 83.5 * no mucositis. * age: 18-75 years * life expectancy ≥ 3 months. * informed consent obtained from the patient. * affiliation with a social security system. exclusion criteria: * tumour of nasopharynx * mucositis * severe sepsis * treatment by immunomodulators in the month preceding inclusion * atcd allergy to the components of oral impact. * parenteral nutrition at inclusion * usual contraindications to concomitant radio-chemotherapy * patient already included in another therapeutic trial involving an experimental molecule * female pregnant or susceptible to being pregnant, or breast-feeding. patient not using appropriate contraceptive measures during the treatment * persons deprived of liberty or under guardianship * patients unable to commit to the trial schedule for geographical, social or psychological reasons.
mobile phone-based smoking-cessation intervention for chronic patients

Conditions: Smoking Cessation

Summary: the study aims to facilitate mobile phone-based cessation support for chronic patients using a sequential multiple assignment randomized trial (smart) , and combines different effective treatments to enhance engagement and determine the most effective adaptive interventions.

noncommunicable diseases (ncds) , also known as chronic diseases, affect of a large of number of people and cause 41 million death each year, equivalent to 74% of globally mortality. in china, ncds have caused 86% of deaths in the past three decades. tobacco use is a type of modifiable behavioural risk factor for the development of noncommunicable disease and death. it not only increases the risk of developing ncds, but also exacerbates their severity and complications. tobacco causes over 8 million deaths annually. china has the world's largest population of smokers, more than 300 million. tobacco related deaths in china are 1 million per year. smoking cessation is one of the most effective and cost-efficient measures for the prevention and control of ncds. it can reduce the morbidity and mortality rates of ncds and improve the health and quality of life of patients. meanwhile, among current smokers in china, the prevalence of tobacco dependence was 49.7%, smoking cessation services are extremely limited in china, with only 366 clinics nationwide. for smokers with ncds, hospitalization or outpatient treatment due to health problems can be a 'teachable moment' for quit smoking. most physicians are unable to provide comprehensive cessation advice due to time and resource constraints, and chronic patients face many relapse triggers after leaving the hospital. therefore, it is necessary to implement staged and personalized smoking cessation interventions for chronic patients. to facilitate smoking cessation among chronic patients, we propose to use a sequential multiple assignment randomized trial (smart) design. this adaptive approach is a concept of stepped treatment that aims to address the unmet needs of chronic patients and enhance smoking cessation outcomes. the study aims to facilitate mobile phone-based cessation support for chronic patients using a sequential multiple assignment randomized trial (smart) , and combines different effective treatments to enhance engagement and determine the most effective adaptive interventions.

Eligibility criteria:
inclusion criteria: 1. aged 18 or above, reside in zhuhai for next 6 months; 2. smoke at least 1 cigarette or use e-cigarettes daily; 3. having a smartphone and a wechat account, being able to use wechat skillfully; 4. having a diagnosis of at least one chronic disease related to smoking; 5. intent to quit / reduce smoking. exclusion criteria: 1. smokers who have communication barrier (either physically or cognitively) 2. having participation in other smoking cessation programmes or services

Keywords: smoking cessation chronic patients smart design
targeted immunotherapy after myeloablative tbi-based conditioning & allohct in caya with high risk t-cell all & lymphoma

Conditions: T-cell Acute Lymphoblastic Leukemia; T-Cell Acute Lymphoblastic Lymphoma

Summary: a phase i trial to determine the safety of targeted immunotherapy with daratumumab (dara) iv after total body irradiation (tbi)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (hct) for children, adolescents, and young adults (caya) with high risk t-cell acute lymphoblastic leukemia (t-all) or t-cell lymphoblastic lymphoma (t-lly). pre- and post-hct ngs-mrd studies will be correlated with outcomes in children, adolescents, and young adults with t-all undergoing allogeneic hct and post-hct dara treatment. the study will also evaluate t-cell repertoire and immune reconstitution prior to and following dara post-hct treatment and correlate with patient outcomes.

total body irradiation (tbi)-based myeloablative allogeneic hematopoietic stem cell transplantation (hct) using best available donor. daratumumab (dara) treatment post-hct: phase 1: 3 dose levels to determine safety (15 patients) dose expansion cohort (dec): further evaluation of pk and pd (correlative studies/exploratory endpoints) to guide future selection of rp2d (15 patients) treatment schedule: 1. induction: dara iv weekly x 8 doses (weeks 1-8) 2. consolidation: dara iv every 2 weeks x 8 doses (weeks 9-24) 3. maintenance: dara iv every 4 weeks (stop at day +270)

Eligibility criteria:
inclusion criteria: * 0-39yrs * t-cell all in second or subsequent remission (≤ 5% blasts) or relapsed t-cell lly with complete response after re-induction therapy (including secondary malignancy) * planned allogeneic stem cell transplantation with donor identified * performance status ≥ 60% * fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study * meet organ function requirements * signed irb approved informed consent exclusion criteria: * may not have had a prior autologous or allogenic stem cell transplant * may not have uncontrolled, systemic infection at the time of enrollment * known allergies, hypersensitivity, or intolerance to mannitol, sorbitol, corticosteroids, monoclonal antibodies or human proteins, or their excipients * must not be pregnant or actively breast feeding * seropositive for hiv, hepatitis b or hepatitis c * copd * asthma * clinically significant cardiac disease

Keywords: immunotherapy children adolescents young adults
postoperative morbidity and mortality after gastrectomy for gastric cancer: prospective cohort study

Conditions: Patients Who Underwent Gastrectomy With Lymph Node Dissection for Gastric Cancer

Summary: gastric cancer is still one of the main health care issue and gastrectomy with lymph node dissection is the only chance to be cure. even though the development and standardization of gastric cancer surgery, the morbidity of gastric cancer surgery was reported around 20% with less than 1% of mortality in east. in contrast, around 40% of morbidity and 10% of mortality was reported in west. there has been several indexes which can define the complications after surgery, but adapting it into clinical practice is sometimes difficult due to the heterogeneous opinion between surgeons. thus for clear defining the complications after surgery, consensus between many surgeons and prospective cohort study is necessary. the purpose of this study is collecting the complications data after gastric cancer surgery and defining it with every week meeting by at least 6 or more surgeons' discussion.


Eligibility criteria:
inclusion criteria: * patients who had histologically confirmed gastric cancer and are going to underwent gastrectomy * age over 20 years with agree to the study exclusion criteria: * withdrawal of their agreement * vulnerable subjects (ex. pregnancy, disabled to decide by him or herself, cannot understand the study such as mental retardation or foreigner)
observational study for sir-spheres therapy for the treatment of unresectable metastatic liver tumors from primary colorectal cancer

Conditions: Colorectal Neoplasms

Summary: this real-world study tries to collect data reflecting routine use of sir-spheres in patients diagnosed with unresectable liver metastases from metastatic liver tumors from primary colorectal cancer (mcrc) refractory to or intolerant to chemotherapy, in order to assess clinical response in a real-world setting and further validate the safe and appropriate use of sir-spheres in china.

this is a post-market trial evaluating the efficacy and safety of sir-spheres® y-90 resin microspheres for the treatment of unresectable metastatic liver tumors from primary colorectal cancer. patients enrolled should already complete the infusion of sir-spheres® and data are about to be collected both retrospectively and prospectively. 200 patients are anticipated to be enrolled and followed up for up to 24 months.

Eligibility criteria:
inclusion criteria: 1. obtained informed consent for patients to be follow-up prospectively 2. age≥18 years old 3. histologically or pathologically confirmed diagnosis of unresectable metastatic liver tumors from primary colorectal cancer and failed standard of care 4. received sir-spheres® exclusion criteria: 1. special contraindications from package insert, which includes 1. markedly abnormal liver function tests, such as total bilirubin \> 2.0 mg/dl or albumin \<3.0 g/dl 2. portal vein thrombosis in the main trunk 3. disseminated extrahepatic disease 4. previous external beam radiation therapy to the liver 2. women are lactating or pregnant during the study or plan to be pregnant during the study 3. patients with mental illness or cognitive impairment 4. per investigator, patients are non-adherent or reluctant to be followed up

Keywords: metastatic colorectal cancer 90y liver metastases sirt radioembolization sir-spheres microspheres
ascorbic acid to prevent postreperfusion syndrome in liver transplantation

Conditions: Liver Transplantation; Postreperfusion Syndrome; Ascorbic Acid

Summary: the goal of this clinical trial is to test the efficacy of intravenous ascorbic acid in preventing the postreperfusion syndrome in liver transplantation. the main questions it aims to answer are: * can intravenous ascorbic acid prevent postreperfusion syndrome in liver transplantation ? * can ascorbic acid decrease the incidence of liver graft dysfunction after liver transplantation? * can ascorbic acid decreased the incidence of postoperative complications after liver transplantation ? participants will receive 1.5 g of intravenous ascorbic acid diluted in 100 ml of saline or 100 ml of saline alone, during the anhepatic phase of liver transplantation before reperfusion of the new graft. researchers will compared the incidence of postreperfusion syndrome in both groups.

researches will compared: * incidence of postreperfusion syndrome in liver transplantation * changes in interleukin values and other inflammatory markers before and after transplantation * incidence of liver graft dysfunction between groups * incidence of acute renal failure and other complications between groups

Eligibility criteria:
inclusion criteria: * patients undergoing liver transplantation exclusion criteria: * pregnancy * allergy to ascorbic acid * nephrolithiasis * glucose-6-phosphate dehydrogenase (g6pd) deficiency * hyperoxaluria * hyperuricemia * haemochromatosis * sickle cell anemia * serum creatinine \> 1.2 mg/dl in women and 1.3 mg/dl in men * split liver graft * acute liver failure * living donor liver transplantation * controlled donor asystolia * treatment with: indinavir, vitamin b12, cyclosporine, iron, deferoxamine, disulfiram

Keywords: postreperfusion syndrome
a real-world study of β-thalassemia major treatment with luspatercept in taiwan

Conditions: β-Thalassemia Major

Summary: this real-world study will assess the efficacy and safety of luspatercept treatment for β-thalassemia major in taiwan as well as the impact on quality of life.


Eligibility criteria:
inclusion criteria: * participants ≥18 years of age. * participants with the diagnosis of transfusion-dependent β-thalassemia major who are eligible to the treatment of luspatercept. * before luspatercept treatment, participant's transfusion burden ≥ 24 red blood cell units in 24 weeks, without ≥35-day transfusion free. exclusion criteria: * hypersensitivity to the active substance or to any of the excipients. * pregnancy. * participants requiring treatment to control the growth of extramedullary hematopoiesis (emh) masses.

Keywords: β-thalassemia major
access registry: a post market follow-up study to monitor the safety, performance and usability of occlutech accessory medical devices

Conditions: Heart Diseases

Summary: the registry is an international, multicenter, non-randomized, non-invasive study to assess the safety, performance and usability of the occlutech accessories "occlutech delivery set (ods), occlutech pistol pusher (opp), occlutech occlusions-pusher (oop) and occlutech sizing balloon (osb)" used for implantation procedures (catheter-based interventions) of cardiac implants via completing surveys (questionnaires) for the accessory medical devices by the investigators.

the registry is an international, multicenter, non-randomized, non-invasive study to assess the safety, performance and usability of the occlutech accessories "occlutech delivery set (ods), occlutech pistol pusher (opp), occlutech occlusions-pusher (oop) and occlutech sizing balloon (osb)" used for implantation procedures (catheter-based interventions) of cardiac implants via completing surveys (questionnaires) for the accessory medical devices by the investigators. a survey (questionnaire) of each accessory medical device should be completed by investigator in order to assess safety of the accessory by success of implantation procedure, occurrence of adverse events during implantation procedure or as late term effects resulting from implantation procedure, user harm related to the accessory, procedure, reported device deficiencies related to the accessory. the surveys (questionnaires) also include questions related to performance, usability and compatibility with devices and other accessories. subjects should be treated according to instructions-for-use of the implants and accessories and according to clinical routine. the devices must have been used exclusively by physicians who are experienced in cardiac catheterization techniques and who are experienced in using the products in the process of interventional operations.

Eligibility criteria:
inclusion criteria: * inclusion criteria depend exclusively on the requirements outlined in the applicable instruction for use for accessory medical devices and cardiac implant devices. all subjects who underwent implantation procedure with an occlutech accessory medical device and cardiac implants can be included exclusion criteria: * exclusion criteria depend exclusively on the requirements outlined in the applicable instruction for use and if applicable in the corresponding protocol of the investigation on the occlutech implant devices.
atomoxetine vs placebo in the treatment of adhd in swedish children and adolescents

Conditions: Attention Deficit Hyperactivity Disorder

Summary: comparison of the effect of atomoxetine and psychoeducation with placebo and psychoeducation after 10 weeks of treatment


Eligibility criteria:
inclusion criteria: * meet the criteria for adhd of the diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv) as well as severity criteria. diagnosis is assessed by the investigator's clinical evaluation as well as administration of the k-sads-pl structured interview. * meet a symptom severity threshold of 1.5 standard deviations above age and sex norms for their diagnostic subtype on the adhdrs-iv-parent: investigator-administered and scored (adhdrs-iv-parent:inv) this severity threshold must be met at visit 1 and maintained at visit 2. * be at least 7 years of age, but not yet have reached their 16th birthday prior to visit 1, when informed consent is obtained. * for female subjects of child-bearing potential only, test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use a reliable method of birth control. exclusion criteria: * weigh less than 20 kg at study entry * have a documented history of bipolar disorder or any history of psychosis or pervasive development disorder (autistic spectrum disorder). * are pregnant or breastfeeding. * are at serious suicidal risk as assessed by the investigator. * have been treated previously for adhd with pyschostimulants such as methylphenidate or ritalin
a safety and efficacy study of travoprost 0.004% compared to latanoprost 0.005% in patients with open-angle glaucoma (oag) or ocular hypertension (oht)

Conditions: Glaucoma, Open-Angle; Ocular Hypertension

Summary: the purpose of this study is to evaluate the safety and iop-lowering efficacy of travoprost (0.004%) compared to latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.


Eligibility criteria:
adult patients of any race and either sex with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension.

Keywords: glaucoma poag oag oht